Asoprisnil

Asoprisnil
Clinical data
ATC code none
Identifiers
CAS Number 199396-76-4 N
PubChem (CID) 9577221
IUPHAR/BPS 2883
ChemSpider 7851660 YesY
UNII 72W09924WP YesY
KEGG D02996 YesY
ChEMBL CHEMBL267431 YesY
Chemical and physical data
Formula C28H35NO4
Molar mass 449.582 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Asoprisnil (J867) is an investigational selective progesterone-receptor modulator developed by Schering and TAP Pharmaceutical Products, tested for treatment of progesterone-sensitive myomata.[1]

In 2005, phase-III trials were discontinued due to endometrial changes in patients. Whether asoprisnil will be marketed is uncertain.[2]

References

  1. DeManno D, Elger W, Garg R, et al. (2003). "Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy". Steroids. 68 (10-13): 1019–32. doi:10.1016/j.steroids.2003.09.008. PMID 14667995.
  2. Schering Interim Report Q1-3 2005


This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.